Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Laurus Labs
LAURUSLABS
Laurus Labs
Rising Regulation And Competition Will Weaken Prospects Despite CDMO Upside
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 13 Analysts
Published
07 Jul 25
Updated
24 Jul 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹305.61
173.6% overvalued
intrinsic discount
24 Jul
₹836.20
Loading
1Y
93.6%
7D
-5.1%
Author's Valuation
₹305.6
173.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹305.6
173.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
81b
2015
2017
2019
2021
2023
2025
2027
2028
Revenue ₹81.1b
Earnings ₹8.6b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.84%
Pharma revenue growth rate
1.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹8.65b
Earnings '28
x
26.50x
PE Ratio '28
=
₹229.18b
Market Cap '28
₹229.18b
Market Cap '28
/
525.51m
No. shares '28
=
₹436.10
Share Price '28
₹436.10
Share Price '28
Discounted to 2025 @ 12.55% p.a.
=
₹305.90
Fair Value '25